Related Experiment Video

Updated: May 29, 2025

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Adenosine Receptor 3 in Liver Cancer: Expression Variability, Epigenetic Modulation, and Enhanced Histone Deacetylase

Louise Kaldjob-Heinrich¹, Sandro Nuciforo^2,3, Steffen Lemke^4,5

¹Department Internal Medicine I, Eberhard-Karls University, Tuebingen, Germany.

Gastro Hep Advances

|February 6, 2025

Abstract

Background And Aims:

Primary liver cancer, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), has low response rates to existing treatments, highlighting the urgent need for novel treatment options. Adenosine A3 receptor (ADORA3) signaling has emerged as a potential target. Namodenoson, an ADORA3 agonist, has shown promise in early clinical trials for HCC. However, further data are required to clarify ADORA3 expression patterns in liver cancer, mechanisms of action, and the potential for combination therapies to inform patient selection for future clinical trials.

Methods:

Patient-derived tissue microarrays and RNA-sequencing were employed to investigate ADORA3 expression. Cellular responses to ADORA3 stimulation and combination treatments were studied in HCC and CCA cell lines and patient-derived organoids (PDOs). Genome-wide RNA-Seq analysis, mRNA analysis, and DigiWest protein profiling were performed.

Results:

Tissue microarray analysis revealed higher ADORA3 expression in nonmalignant samples and a subset of tumors with weak or absent ADORA3 expression. This was supported by RNA sequencing data from The Cancer Genome Atlas and needle biopsy samples. Cell lines and PDOs exhibited antiproliferative effects with the ADORA3 agonist Namodenoson, confirmed by receptor dependency tests with specific antagonists and siRNA experiments. Genome-wide RNA-Seq analysis suggested chromatin remodeling events after ADORA3 stimulation. mRNA expression and DigiWest profiling identified downregulation of histone deacetylases and histone H3 modifications. Combination treatments with different ADORA3 agonists and histone deacetylase inhibitors significantly enhanced antiproliferative effects in almost all selected combinations, supported by investigations in PDOs.

Conclusion:

ADORA3 expression varies considerably in HCC or CCA, ranging from high to absent receptor detection. This observation might help to identify patients for clinical studies. Additionally, Namodenoson's epigenetic modulating activity suggests epigenetic drugs as promising candidates for combination treatment.

Insights

Novel liver cancer treatments targeting Adenosine A3 receptor (ADORA3) show promise. Namodenoson, an ADORA3 agonist, combined with epigenetic drugs, demonstrated significant anti-cancer effects in hepatocellular carcinoma and cholangiocarcinoma models.

Area of Science:

Oncology
Molecular Biology
Pharmacology

Background:

Primary liver cancer, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), has limited treatment options.
Adenosine A3 receptor (ADORA3) signaling is a potential therapeutic target.
Namodenoson, an ADORA3 agonist, has shown early promise in HCC clinical trials.

Purpose of the Study:

To investigate ADORA3 expression patterns in liver cancer.
To elucidate the mechanisms of action of ADORA3 agonists.
To evaluate combination therapies involving ADORA3 agonists for HCC and CCA.

Main Methods:

Patient-derived tissue microarrays and RNA-sequencing were used to assess ADORA3 expression.
Cellular responses to ADORA3 stimulation and combination treatments were studied in HCC/CCA cell lines and patient-derived organoids (PDOs).
Genome-wide RNA-Seq, mRNA analysis, and DigiWest protein profiling were performed.

Main Results:

ADORA3 expression varied significantly in HCC and CCA tumors, with higher expression in nonmalignant tissues.
The ADORA3 agonist Namodenoson exhibited antiproliferative effects in cancer cell lines and PDOs, dependent on ADORA3.
Combination treatments with ADORA3 agonists and histone deacetylase inhibitors enhanced antiproliferative effects, suggesting epigenetic modulation.

Conclusions:

ADORA3 expression levels can potentially stratify patients for clinical studies in HCC and CCA.
Namodenoson's epigenetic effects indicate that epigenetic drugs are promising partners for combination therapy.
Targeting ADORA3 signaling offers a novel therapeutic strategy for liver cancer, particularly in combination regimens.

Read full analysis

Keywords:

Adenosine Receptor 3 Cancer Combination Therapy Cholangiocarcinoma Epigenetic Hepatocellular Carcinoma

More Related Videos

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

Global Level Quantification of Histone Post-Translational Modifications in a 3D Cell Culture Model of Hepatic Tissue

Global Level Quantification of Histone Post-Translational Modifications in a 3D Cell Culture Model of Hepatic Tissue

Published on: May 5, 2022

Related Concept Videos

Epigenetic Regulation

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...

Cell Specific Gene Expression

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...

Histone Modification

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...

Articles linked to this work by shared authors, journal, and citation graph.

Thinking Outside the Binding Site: A Self-Encapsulating Kinase Inhibitor Remodels Its Pocket to Achieve Selectivity.

Angewandte Chemie (International ed. in English)·2026

Pregnane X receptor-mediated liver growth: a controlled clinical trial in healthy volunteers and identification of the role of AKT-MTOR pathway in mouse.

Archives of toxicology·2026

Hepatocellular carcinoma organoids enable drug discovery and combination therapy across heterogeneous tumors.

Cell reports·2026

Accurate quantification of spliced and unspliced transcripts for single-cell RNA sequencing with tidesurf.

PloS one·2026

SHIELD: A weakly supervised graph attention neural network for decoding disease-relevant cell-cell interactions.

Patterns (New York, N.Y.)·2026

Screen for Tissue-Specific Markers of Drug-Induced Phospholipidosis Using Mass Spectrometry Imaging.

Journal of the American Society for Mass Spectrometry·2026

See all related articles